	US 11,672,854 B2
	Multivalent live influenza vaccine platform using recombinant adenovirus
Hyun Joo Youn, Gimhae-si (KR); and Eun Yeong Han, Seoul (KR)
Assigned to INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Gimhae-si (KR); and GENEUIN-TECH CO., LTD., Gimhae-si (KR)
Appl. No. 16/980,838
Filed by INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Gimhae-si (KR); and GENEUIN-TECH CO., LTD., Gimhae-si (KR)
PCT Filed Jan. 16, 2019, PCT No. PCT/KR2019/000651 § 371(c)(1), (2) Date Sep. 14, 2020, PCT Pub. No. WO2019/177256, PCT Pub. Date Sep. 19, 2019.
Claims priority of application No. 10-2018-0029823 (KR), filed on Mar. 14, 2018.
Prior Publication US 2021/0361763 A1, Nov. 25, 2021
Int. Cl. A61K 39/145 (2006.01); A61P 31/16 (2006.01); C12N 15/86 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/145 (2013.01) [A61P 31/16 (2018.01); C07K 14/005 (2013.01); C12N 15/86 (2013.01); A61K 2039/543 (2013.01); A61K 2039/552 (2013.01); A61K 2039/70 (2013.01)]

9 Claims

1. A recombinant fusion protein of influenza A virus H5 type hemagglutinin 1 (HA1) and H7 type HAL which is obtained from a recombinant adenovirus strain transfected with a recombinant expression vector comprising an influenza A virus H5 type hemagglutinin 1 (HA1) gene and an influenza A virus H7 type HA1 gene.